TherapeuticsMD, Inc DEFA14A, filed May 4, 2020

TherapeuticsMD, Inc. (TXMD)

DEFA14A 2020-05-04

Added on October 26, 2026


☐		Preliminary Proxy Statement
☐		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐		Definitive Proxy Statement
☒		Definitive Additional Materials
☐		Soliciting Material Pursuant to §240.14a-12


☒	No fee required.
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

	1)	Title of each class of securities to which transaction applies:
	2)	Aggregate number of securities to which transaction applies:
	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	4)	Proposed maximum aggregate value of transaction:
	5)	Total fee paid:

☐	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	1)	Amount previously paid:
	2)	Form, Schedule or Registration Statement No.:
	3)	Filing party:
	4)	Date Filed:


The Board of Directors recommends you vote FOR the following:

1.	Election of Directors Nominees: 01) Paul M. Bisaro 02) J. Martin Carroll 03) Cooper C. Collins 04) Robert G. Finizio 05) Karen L. Ling	06) Jules A. Musing 07) Gail K. Naughton, Ph.D. 08) Angus C. Russell 09) Tommy G. Thompson


The Board of Directors recommends you vote FOR the following proposal:

2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2019 (say-on-pay);

The Board of Directors recommends you vote FOR the following proposal:

3.	To approve an amendment to the Amended and Restated Articles of Incorporation, as amended, to increase the number of authorized shares of common stock, $0.001 par value per share, from 350,000,000 shares to 600,000,000 shares;

The Board of Directors recommends you vote FOR the following proposal:

4.	To approve the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan;

The Board of Directors recommends you vote FOR the following proposal:

5.	To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2020;

and upon such other business as may properly come before the meeting or any adjournment thereof.


*Location:**		Renaissance Boca Raton Hotel
		2000 NW 19th Street Boca Raton, Florida 33431


		See the reverse side of this notice to obtain proxy materials and voting instructions.